RAC1 and systemic mastocytosis: Similarly to MA9 AML, in murine cells expressing KITD814V, a mutation found in about 40% of AML cases and in about 90% of systemic mastocytosis (SM) cases, and treatment with EHop-016, an inhibitor that targets Rac1 and Rac2 (discussed in more detail in Section 5.1), resulted in reduced proliferation and cell viability due to enhanced apoptosis through repression of the Bcl-2 family member, Bad [57].